scholarly journals Impaired Healing

2020 ◽  
Author(s):  
Keyword(s):  
Impaired Healing

Impaired Healing Because of Copper Deficiency in a Pediatric Burn Patient: A Case Report

2008 ◽  
Vol 65 (2) ◽  
pp. 464-466 ◽  
Author(s):  
Rungsinee A. Liusuwan ◽  
Tina Palmieri ◽  
Nancy Warden ◽  
David G. Greenhalgh
Keyword(s):  
Case Report ◽  
Copper Deficiency ◽  
Impaired Healing ◽  
Burn Patient

Nitric oxide restores impaired healing in normoglycaemic diabetic rats

2007 ◽  
Vol 16 (7) ◽  
pp. 311-316 ◽  
Author(s):  
M. Schaffer ◽  
M. Bongartz ◽  
S. Fischer ◽  
R. Viebahn ◽  
B. Proksch
Keyword(s):  
Nitric Oxide ◽  
Diabetic Rats ◽  
Impaired Healing

Impact of bevacizumab chemotherapy on craniotomy wound healing

2011 ◽  
Vol 114 (6) ◽  
pp. 1609-1616 ◽  
Author(s):  
Aaron J. Clark ◽  
Nicholas A. Butowski ◽  
Susan M. Chang ◽  
Michael D. Prados ◽  
Jennifer Clarke ◽  
...  
Keyword(s):  
Wound Healing ◽  
Recurrent Glioblastoma ◽  
Csf Leak ◽  
Categorical Variables ◽  
Complication Rates ◽  
Phase Ii Trials ◽  
Impaired Wound Healing ◽  
The Third ◽  
Impaired Healing ◽  
Bevacizumab Treatment

Object The FDA approval of bevacizumab for recurrent glioblastoma has resulted in its increased use in this patient population. Phase II trials reported 4%–6% impaired wound healing for bevacizumab initiated postoperatively. The effect of preoperative bevacizumab on subsequent craniotomy healing has not been addressed. Methods The authors retrospectively reviewed the cases of patients who underwent craniotomy for recurrent glioblastoma between 2005 and 2009, evaluating bevacizumab therapy/duration and healing complications (dehiscence, pseudomeningocele, CSF leak, and wound/bone infection). The Wilcoxon rank-sum test and Kruskal-Wallis test were used to compare continuous variables between groups. The Fisher exact test was used to assess for an association between categorical variables, including the comparison of wound-healing complication rates. Logistic regression models were used to estimate odds ratios of wound-healing complications while adjusting for baseline variables. Results Two hundred nine patients underwent a second craniotomy (161 patients) or third craniotomy (48 patients) for recurrent glioblastoma. Twenty-six individuals (12%) developed wound-healing complications. One hundred sixty-eight patients received no bevacizumab, 23 received preoperative bevacizumab, and 18 received postoperative bevacizumab. Significantly more patients receiving preoperative bevacizumab developed healing complications (35%) than non–bevacizumab-treated patients (10.0%, p = 0.004). Postoperative bevacizumab was associated with 6% impaired healing, not significantly different from non–bevacizumab-treated controls (p = 1.0). Preoperative bevacizumab treatment duration (weeks) did not influence healing (OR 0.98, p = 0.55). More healing complications occurred in patients receiving preoperative bevacizumab than in non–bevacizumab-treated controls before the third craniotomy (44% vs 9%, p = 0.03). Conclusions Although subject to the limitations of a retrospective study, we demonstrate that preoperative bevacizumab treatment resulted in impaired healing after a second and third craniotomy, compared with minimal effect of postoperative bevacizumab. This effect is more striking for the third craniotomy and for a shorter delay between bevacizumab and surgery. These complications should be acknowledged as increased bevacizumab use results in more post–bevacizumab-treated patients in whom surgery for recurrent glioblastoma is considered. Based on these results, the authors recommend performing repeated craniotomy more than 28 days after last administered dose of bevacizumab whenever possible.

The Biology of Impaired Healing of Joint Tissues

2013 ◽  
pp. 101-112
Author(s):  
Martha M. Murray
Keyword(s):  
Impaired Healing

scholarly journals Abnormal Cell Responses and Role of TNF-αin Impaired Diabetic Wound Healing

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Fanxing Xu ◽  
Chenying Zhang ◽  
Dana T. Graves
Keyword(s):  
Wound Healing ◽  
Macrophage Polarization ◽  
Diabetic Wound ◽  
Major Health Problem ◽  
Abnormal Cell ◽  
Fibroblast Migration ◽  
Cell Responses ◽  
Impaired Healing ◽  
Diabetic Wound Healing

Impaired diabetic wound healing constitutes a major health problem. The impaired healing is caused by complex factors such as abnormal keratinocyte and fibroblast migration, proliferation, differentiation, and apoptosis, abnormal macrophage polarization, impaired recruitment of mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), and decreased vascularization. Diabetes-enhanced and prolonged expression of TNF-αalso contributes to impaired healing. In this paper, we discuss the abnormal cell responses in diabetic wound healing and the contribution of TNF-α.

Wound healing complications with lenvatinib identified in a pharmacovigilance database

2018 ◽  
Vol 25 (8) ◽  
pp. 1817-1822 ◽  
Author(s):  
Connie Cheng ◽  
Afrouz Nayernama ◽  
S Christopher Jones ◽  
Denise Casey ◽  
Peter E Waldron
Keyword(s):  
Wound Healing ◽  
Kinase Inhibitors ◽  
Tissue Injury ◽  
Risk Mitigation ◽  
Adverse Event Reporting System ◽  
Case Series ◽  
Wound Dehiscence ◽  
Safety Risk ◽  
Impaired Healing ◽  
Wide Range

The U.S. Food and Drug Administration (FDA) has approved several vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors, including lenvatinib, for thyroid and renal malignancies. Inhibition of the VEGFR signaling pathway impairs angiogenesis and can disrupt wound healing. The objective of this work was to evaluate wound healing complications as a potential safety risk for patients treated with lenvatinib. We searched the FDA Adverse Event Reporting System (FAERS) database for postmarketing reports of wound healing complications with lenvatinib between 13 February 2015 (FDA approval date) and 15 February 2017. The search identified nine FAERS cases of lenvatinib-associated wound healing complications that were not previously reported in the medical literature. Seven cases involved postoperative wound healing complications, such as impaired healing or wound dehiscence. In our case series, the reported time to identification of delayed wound healing from tissue injury or surgery varied over a wide range (4–58 days). The time of initial lenvatinib exposure relative to the tissue injury was also highly varied in our series, which may have influenced the development and detection of impaired healing. FAERS case-level evidence suggests that lenvatinib may have contributed to wound healing complications based on temporality and biologic plausibility. Healthcare professionals should be aware of this safety risk to facilitate prompt recognition and risk mitigation.

Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor

2003 ◽  
Vol 1 (10) ◽  
pp. 2087-2096 ◽  
Author(s):  
E. A. Te Velde ◽  
G. T. M. Wagenaar ◽  
A. Reijerkerk ◽  
M. Roose-Girma ◽  
I. H. M. Borel Rinkes ◽  
...  
Keyword(s):  
Thrombin Activatable Fibrinolysis Inhibitor ◽  
Colonic Anastomoses ◽  
Cutaneous Wounds ◽  
Impaired Healing ◽  
Fibrinolysis Inhibitor

scholarly journals Impaired healing of neuropathic foot ulcers due to neuropathic bladder distension in a patient with diabetes.

BMJ ◽  
1990 ◽  
Vol 301 (6746) ◽  
pp. 281-281
Author(s):  
E A Masson ◽  
I A MacFarlane
Keyword(s):  
Foot Ulcers ◽  
Bladder Distension ◽  
Neuropathic Bladder ◽  
Impaired Healing ◽  
Neuropathic Foot

Changes in the plasma cytokine and growth factor profile are associated with impaired healing in pediatric patients treated with INTEGRA® for reconstructive procedures

Burns ◽  
2013 ◽  
Vol 39 (4) ◽  
pp. 667-673 ◽  
Author(s):  
Michal Nessler ◽  
Jacek Puchala ◽  
Fiona M. Wood ◽  
Hilary J. Wallace ◽  
Mark W. Fear ◽  
...  
Keyword(s):  
Growth Factor ◽  
Pediatric Patients ◽  
Plasma Cytokine ◽  
Reconstructive Procedures ◽  
Impaired Healing
Sign in / Sign up

Export Citation Format

Share Document